Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.

Krischke M, Hempel G, Völler S, André N, D'Incalci M, Bisogno G, Köpcke W, Borowski M, Herold R, Boddy AV, Boos J.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1175-1184.

2.

Doxorubicin induced heart failure: Phenotype and molecular mechanisms.

Mitry MA, Edwards JG.

Int J Cardiol Heart Vasc. 2016 Mar;10:17-24.

3.

Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.

Moudgil R, Yeh ET.

Can J Cardiol. 2016 Jul;32(7):863-870.e5. doi: 10.1016/j.cjca.2016.01.027. Review.

PMID:
27117975
4.

Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification.

Li DL, Wang ZV, Ding G, Tan W, Luo X, Criollo A, Xie M, Jiang N, May H, Kyrychenko V, Schneider JW, Gillette TG, Hill JA.

Circulation. 2016 Apr 26;133(17):1668-87. doi: 10.1161/CIRCULATIONAHA.115.017443.

PMID:
26984939
5.

Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.

Lipshultz SE, Anderson LM, Miller TL, Gerschenson M, Stevenson KE, Neuberg DS, Franco VI, LiButti DE, Silverman LB, Vrooman LM, Sallan SE; Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium..

Cancer. 2016 Mar 15;122(6):946-53. doi: 10.1002/cncr.29872.

PMID:
26762648
6.

Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.

Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, Stovall M, Oeffinger KC, Bhatia S, Krull KR, Nathan PC, Neglia JP, Green DM, Hudson MM, Robison LL.

N Engl J Med. 2016 Mar 3;374(9):833-42. doi: 10.1056/NEJMoa1510795.

7.

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.

Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE.

J Clin Oncol. 2016 Mar 10;34(8):854-62. doi: 10.1200/JCO.2015.60.8851.

PMID:
26700126
8.

Investigation of Fatty Acid Ketohydrazone Modified Liposome's Properties as a Drug Carrier.

Hayashi K, Kiriishi M, Suga K, Okamoto Y, Umakoshi H.

J Drug Deliv. 2015;2015:481670. doi: 10.1155/2015/481670.

9.

Therapeutic targeting of autophagy in cardiovascular disease.

Schiattarella GG, Hill JA.

J Mol Cell Cardiol. 2016 Jun;95:86-93. doi: 10.1016/j.yjmcc.2015.11.019. Review.

PMID:
26602750
10.

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ; Canadian Pharmacogenomics Network for Drug Safety Consortium..

Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374.

11.

Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.

Lee YR, Kang MH, Park HM.

Can Vet J. 2015 Jun;56(6):571-4.

12.

NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.

Zidan A, Sherief LM, El-sheikh A, Saleh SH, Shahbah DA, Kamal NM, Sherbiny HS, Ahmad H.

Dis Markers. 2015;2015:513219. doi: 10.1155/2015/513219.

13.

CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia.

Krishnan V, Xu X, Kelly D, Snook A, Waldman SA, Mason RW, Jia X, Rajasekaran AK.

Mol Pharm. 2015 Jun 1;12(6):2101-11. doi: 10.1021/acs.molpharmaceut.5b00071.

14.

Impairments that influence physical function among survivors of childhood cancer.

Wilson CL, Gawade PL, Ness KK.

Children (Basel). 2015;2(1):1-36. doi: 10.3390/children2010001.

15.

Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program.

Barlogis V, Auquier P, Bertrand Y, Chastagner P, Plantaz D, Poiree M, Kanold J, Berbis J, Oudin C, Vercasson C, Allouche M, Tabone MD, Thouvenin-Doulet S, Saumet L, Chambost H, Baruchel A, Leverger G, Michel G.

Haematologica. 2015 May;100(5):e186-9. doi: 10.3324/haematol.2014.116574. No abstract available.

16.

Cardiovascular disease in adult survivors of childhood cancer.

Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE.

Annu Rev Med. 2015;66:161-76. doi: 10.1146/annurev-med-070213-054849. Review.

17.

Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine.

Bernstein D, Burridge P.

Prog Pediatr Cardiol. 2014 Dec 1;37(1-2):23-27. No abstract available.

18.

Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells.

Holmgren G, Synnergren J, Bogestål Y, Améen C, Åkesson K, Holmgren S, Lindahl A, Sartipy P.

Toxicology. 2015 Feb 3;328:102-11. doi: 10.1016/j.tox.2014.12.018.

19.

Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.

Stachowiak P, Kornacewicz-Jach Z, Safranow K.

Arch Med Sci. 2014 Oct 27;10(5):1007-18. doi: 10.5114/aoms.2013.34987.

20.

Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.

Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ, Goyal S.

Front Oncol. 2014 Oct 9;4:277. doi: 10.3389/fonc.2014.00277. Review.

Items per page

Supplemental Content

Support Center